NO CALL ON RECORD
the engine publishes a call only when every gate clears
SEE THE LEDGER →FINNENCE ▪ THE ASSET FILE
PERMANENT ASSET RECORD · TRACKED BY FINNENCE
XBI
SPDR Biotech ETF
$161.87
LAST CLOSE2026-09-22 · +2.3%SPDR Biotech ETF — 48 stories tracked over the last 30 days. No call on record.
LAST $161.87·Δ1D +2.3%·Δ20D -1.4%·60D RANGE $147.01–$169.55·FROM 60D HIGH -4.5%·THEMES 1
SECTION 01 · THE MACHINE'S FILE
WHAT FINNENCE THINKS.
NO OPEN PAPER POSITION
the $1K paper fund holds nothing here
VIEW THE PAPER FUND →THEME CONTEXT
Biotech
EMERGINGANCHOR · SCORE 0.575
RS20 -0.029506
NO ABNORMAL MOVES FLAGGED IN THE LAST 45 DAYS
the scanner re-runs hourly; flags land on the radar
ON THE RADAR →SECTION 02 · THE PRICE RECORD
NINETY SESSIONS, ONE LINE.
LAST$161.87Δ1D+2.3%Δ20D-1.4%60D RANGE$147.01–$169.55
INTERACTIVE PRICE — TRADINGVIEW
INTERACTIVE CHART — LOADS WHEN VISIBLE
SECTION 03 · THE STORY FLOW
WHAT THE FEED SAW.
Recent stories2026-09-22 07:14 UTCNEWSUNCLEARIambic maintains momentum from string of Big Pharma partnerships by aiming for IPO - Fierce Biotech
2026-09-21 18:24 UTCNEWSUNCLEARSEC-FDA Information-Sharing MOU: Implications for Pharma and Biotech - Morgan Lewis
2026-09-21 16:40 UTCNEWSUNCLEARRNA drug developer ADARx seeks $1.74 billion valuation in US IPO - The Mighty 790 KFGO
2026-09-21 12:50 UTCNEWSUNCLEARADRX IPO News - siRNA biotech ADARx Pharmaceuticals sets terms for $350 million IPO - renaissancecapital.com
2026-09-21 11:40 UTCNEWSBEARISHElectra raises $350m in IPO as shares slip on Nasdaq debut - The Pharma Letter
2026-09-21 10:42 UTCNEWSUNCLEARADARx Pharmaceuticals targets $1.74 billion valuation in US IPO - Reuters
2026-09-21 10:34 UTCNEWSUNCLEARRNA drug developer ADARx seeks $1.74 billion valuation in US IPO - Bradenton Herald
2026-09-21 08:29 UTCNEWSMIXEDRetension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede - Fierce Biotech
2026-09-21 08:29 UTCNEWSBULLISHRetension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede - fiercebiotech.com
2026-09-20 23:28 UTCNEWSMIXEDRadiopharma companies merge after one receives surprise FDA rejection - STAT
2026-09-20 21:11 UTCNEWSUNCLEARElectra Therapeutics Prices $350 Million In Upsized IPO To Advance Precision Medicines For Immune Diseases And Cancer - Pulse 2.0
2026-09-18 22:39 UTCNEWSMIXEDRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues - WTVB
SECTION 04 · CATALYSTS
NO CATALYSTS ON THE CALENDAR.
LATEST PRICES
2026-09-22 00:00 UTCyfinance$161.03 +0.0%
2026-09-21 00:00 UTCyfinance$157.61 +0.0%
2026-09-18 00:00 UTCyfinance$157.52 -0.0%
2026-09-17 00:00 UTCyfinance$158.02 +0.0%
2026-09-16 00:00 UTCyfinance$155.38 +0.0%
2026-09-15 00:00 UTCyfinance$154.27 -0.0%
2026-09-14 00:00 UTCyfinance$157.01 +0.0%
2026-09-11 00:00 UTCyfinance$156.20 -0.0%
METHODOLOGY · PAPER ONLY
OPEN THE MACHINE →A permanent, data-backed asset record. Calls are immutable; market data and machine detections update. PAPER ONLY · NOT FINANCIAL ADVICE.
INSPECT THE PAPER FUND →